The COVID Pill
Description
In the race to end the pandemic, pharmaceutical companies have been working on therapeutics to reduce the risk of hospitalizations and death from COVID-19. One of those companies, Merck, just recently announced an oral antiviral drug that supposedly reduces the risk of hospitalization and death by approximately 50% compared to placebo patients.
While Merk pursues Emergency Use Authorization for their drug, Molnupiravir, we provide a breakdown of the history of this drug, how it came to be, and where the research stands on this so-called "miracle drug".
Subscribe to the Health Hackd Newsletter
Rate the show on Apple Podcast
Follow along on Instagram
Try the cleanest, most effective electrolyte drink on the market: Drink LMNT
Resources
- History of Molnupiravir
- Merck Announces Supply Agreement with U.S. Government for Molnupiravir
- Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo
- Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19
- β-D-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells
- Fluvoxamine, Ivermectin, Vitamin D, and L-arginine
- Merck’s Covid Pill Could Pose Serious Risks, Scientists Warn
Disclaimer
This podcast is not intended to provide medical advice, diagnosis, or treatment. The products, information, services, and other content provided on and through this podcast, including information that may be provided in the show notes (directly or via linking to third-party sites), are provided for informational purposes only. Please consult with your physician or other healthcare professionals regarding any medical or health-related diagnosis or treatment options.
United States
